XML 47 R40.htm IDEA: XBRL DOCUMENT v3.25.2
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized $ 1,348 $ 998 $ 4,088 $ 26,363
AstraZeneca Agreements [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized 16,400 46,000 53,300 73,100
Drug Product Revenue, Net [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized 1,215 729 3,811 25,216
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized 1,200 700 3,800 (500)
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Japan [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized 44 (366) 1,825 (2,571)
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Europe [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized 1,171 1,095 1,986 2,116
Drug Product Revenue, Net [Member] | AstraZeneca Agreements [Member] | U.S. [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized $ 0 $ 0 $ 0 $ 25,671